Century Therapeutics, Inc. (NASDAQ:IPSC), featuring a year-to-date gain of 114.11% and upside potential of 134.70%, secures a spot on our list of hot biotech stocks under $5 to buy. New preclinical ...

Human induced pluripotent stem cells (iPSCs) have a great potential for scientific and medical applications. They are used in research laboratories to model human diseases, helping to uncover ...

Pluristyx, a leading provider of advanced induced pluripotent stem cell (iPSC) technologies and proprietary, genetically engineered solutions, today announced the Japanese Patent Office (JPO) issued a ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...

Many drugs still fail after promising preclinical results, raising difficult questions about how disease is modelled in the ...

DALLAS--(BUSINESS WIRE)--Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced ...

A research team at National Taiwan University has developed a new stem cell-based vaccine that could help prevent and treat colorectal cancer. Their research demonstrates that iPSC-based vaccines can ...

From the discovery of the Yamanaka factors to late-stage clinical trials, induced pluripotent stem cells have revolutionized biomedical science. For the first time, scientists reprogrammed cells from ...